skip navigation links
National Cancer Institute
Enterprise Vocabulary Services
Box
NCIm Version: 201808 (Browser Version 2.9, using LexEVS 6.5.1)
SearchBox Top
SearchBox Bottom
Nintedanib (CUI C2930789) Suggest changes to this concept
Add to Cart

Terms & Properties

Concept Unique Identifier (CUI): C2930789

NCI Thesaurus Code: C62765  (see NCI Thesaurus info)

Semantic Type: Pharmacologic Substance

Semantic Type: Organic Chemical

NCIt Definition: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis.

PDQ Definition: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis. Check for active clinical trials using this agent. (NCI Thesaurus)

NCI-GLOSS Definition: A substance being studied in the treatment of some types of cancer. BIBF 1120 blocks enzymes needed for cells to grow, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.

Synonyms & Abbreviations: (see Synonym Details)
BIBF 1120
BIBF-1120
BIBF1120
Intedanib
METHYL (3Z)-3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLIDENE)-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate
Multitargeted Tyrosine Kinase Inhibitor BIBF 1120
Nintedanib (product)
Nintedanib (substance)
Nintedanib
tyrosine kinase inhibitor BIBF 1120
vargatef

External Source Codes: 
NCI Thesaurus Code C62765 (see NCI Thesaurus info)
CAS Registry Number 656247-17-5 (see NLM ChemIDplus info)
FDA UNII Code G6HRD2P839
PDQ Closed Trial Search ID 504524
PDQ Open Trial Search ID 504524 (check for NCI PDQ open clinical trial info)

Other Properties: Property Definitions
Name Value Source
ACTIVE 1 SNOMEDCT_US
CASE_SIGNIFICANCE_ID 900000000000448009 SNOMEDCT_US
CHARACTERISTIC_TYPE_ID 900000000000011006 SNOMEDCT_US
Chemical_Formula C31H33N5O4 NCI
Contributing_Source CTRP NCI
Contributing_Source FDA NCI
CTV3ID XUroy SNOMEDCT_US
CTV3ID XUt5c SNOMEDCT_US
DATE_FIRST_PUBLISHED 2006-08-24 PDQ
DATE_LAST_MODIFIED 2015-11-04 PDQ
DEFINITION_STATUS_ID 900000000000073002 SNOMEDCT_US
DEFINITION_STATUS_ID 900000000000074008 SNOMEDCT_US
EFFECTIVE_TIME 20150731 SNOMEDCT_US
EFFECTIVE_TIME 20160731 SNOMEDCT_US
FDA_UNII_CODE G6HRD2P839 DRUGBANK
FDA_UNII_CODE G6HRD2P839 NDFRT
FR 138 MSH
HM D007211 MSH
LEVEL Ingredient NDFRT
LT TRD MSH
LT TRD PDQ
MDA 20080814 MSH
MMR 20150311 MSH
MODIFIER_ID 900000000000451002 SNOMEDCT_US
NCI_THESAURUS_CODE C62765 PDQ
NDFRT_KIND DRUG_KIND NDFRT
NUI N0000191096 NDFRT
ORIG_STY Drug/agent PDQ
PA D000970 MSH
PA D004791 MSH
RN 0 MSH
RN G6HRD2P839 MSH
RR 42F62RTZ4G MSH
RXAUI 6800418 RXNORM
RXAUI 6800571 RXNORM
RXAUI 6813850 RXNORM
RXAUI 6817219 RXNORM
RXAUI 6817220 RXNORM
RXCUI 1592737 RXNORM
SC 1 MSH
SOS Boehringer Ingelheim's triple kinase inhibitor blocking VEGFR, PDGFR and FGFR MSH
SPL_SET_ID da1c9f37-779e-4682-816f-93d0faa4cfc9 MTHSPL
SRC Cancer Res 2008 Jun 15;68(12):4774-82 MSH
SUBSET_MEMBER 900000000000497000~MAPTARGET~XUroy SNOMEDCT_US
SUBSET_MEMBER 900000000000497000~MAPTARGET~XUt5c SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
TERMUI T723976 MSH
TERMUI T723977 MSH
TERMUI T723978 MSH
TERMUI T817142 MSH
TERMUI T834767 MSH
TH FDA SRS (2012) MSH
TH INN (19XX) MSH
TH NLM (2008) MSH
TH NLM (2012) MSH
TH NLM (2013) MSH
TH USAN (2010) MSH
TH US MSH
TYPE_ID 900000000000003001 SNOMEDCT_US
TYPE_ID 900000000000013009 SNOMEDCT_US
VANDF_RECORD 50.416^4961^Active/Master NDFRT
VANDF_RECORD 50.6^4959^Active/Master NDFRT
VUID 4033814 NDFRT

Additional Concept Data:  (none)

URL to Bookmark: https://ncim-stage.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=C2930789

Mainbox Bottom